Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

Journal of Immunotherapy

Volumn 31, Issue 8, 2008, Pages 781-791

  Fourcade, Julien ^a   Kudela, Pavol ^a   Andrade Filho, Pedro A ^a   Janjic, Bratislav ^a   Land, Stephanie R ^a   Sander, Cindy ^a   Krieg, Arthur ^a   Donnenberg, Albert ^a   Shen, Hongmei ^a   Kirkwood, John M ^a   Zarour, Hassane M ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Analog peptides; Cancer vaccines; CpG; Melanoma

Indexed keywords

AGATOLIMOD; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; NY ESO 1 157 165V; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; DRUG DERIVATIVE; MANNITOL; MANNITYL OLEATE; OLEIC ACID; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE FRAGMENT; PEPTIDE NY ESO 1 157 165; PEPTIDE NY-ESO-1 157-165; TUMOR PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FEVER; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LYMPHOCYTE DIFFERENTIATION; MALE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; RIGOR; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PILOT STUDY; SKIN TUMOR;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNIZATION; MALE; MANNITOL; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; OLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; PILOT PROJECTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 59849116262     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318183af0b     Document Type: Article

References (31)

1. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Ann Rev Immunol. 2006;24:175-208.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
3. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006;12:2326s-2330s.
4. Baumgaertner P, Rufer N, Devevre E, et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res. 2006;66:1912-1916.
5. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Nat Acad Sci USA. 2007;104:8947-8952.
6. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Nat Acad Sci USA. 1997;94:1914-1918.
7. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
8. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [see comments]. J Exp Med. 1998;187:1349-1354.
9. Chen W, Yewdell JW, Levine RL, et al. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med. 1999;189:1757-1764.
10. + T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res. 2001;7:766s-772s.
11. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000;165:948-955.
12. Chen JL, Stewart-Jones G, Bossi G, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med. 2005;201:1243-1255.
13. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
14. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol. 2002;20:709-760.
15. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Investig. 2005;115:739-746.
16. Zarour H, De Smet C, Lehmann F, et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J Investig Dermatol. 1996;107:63-67.
17. + T cells. Cancer Res. 2000;60:4946-4952.
18. Genevee C, Diu A, Nierat J, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol. 1992;22:1261-1269.
19. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
20. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
21. Khong HT, Yang JC, Topalian SL, et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004;27:472-477.
22. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539-2548.
23. Valmori D, Fonteneau JF, Valitutti S, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol. 1999;11:1971-1980.
24. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000;60:4499-4506.
25. Karbach J, Gnjatic S, Pauligk C, et al. Tumor-reactive CD8(+) T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer. 2007;121:2042-2048.
26. + T cells. J Immunol. 2003;170:1822-1829.
27. Stuge TB, Holmes SP, Saharan S, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004;1:e28.
28. + T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother (1997). 2005;28:252-257.
29. + T lymphocytes. J Immunol. 2007;178:4112-4119.
30. + T cells. Cancer Res. 2004;64:1140-1145.
31. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;1 19:317-327.